APA (7th ed.) Citation

Stone, C. J., Ahuja, G., Gomes, L. L. A., Poroye, J., Faden, D. F., Xie, L., . . . Werth, V. P. Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study. Elsevier.

Chicago Style (17th ed.) Citation

Stone, Caroline J., Geeta Ahuja, Lais Lopes Almeida Gomes, Joy Poroye, Daniella Forman Faden, Lillian Xie, Rui Feng, Barbara White, and Victoria P. Werth. Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study. Elsevier.

MLA (9th ed.) Citation

Stone, Caroline J., et al. Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study. Elsevier.